The four panelists each predict one likely outcome from Digital ILC 2021. Interestingly, none of them focus specifically on clinical trials, but instead on a broader range of issues around understanding the metabolic underpinnings of NASH and determining treatment plans and strategy for today, before the new generation of medications arrives.

TOPICS: Akero Therapeutics, aldafermin, cirrhosis, Diabetes, Diagnostic Tests, DrugTrial, efruxifermin, Fibrosis Level 3, Fibrosis Level 4, NAFLD, NASH, NASH-TAG-2021, NGM Biopharmaceuticals, non-invasive liver testing, TrialDesign, Liver cancer, genetic profiles, genetic therapies, artificial intelligence, histopathology, combination therapies, lifestyle interventions

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast